1. Health Protection Agency. Quarterly Epidemiological Commentary: Mandatory MRSA, MSSA and E. coli bacteraemia, and C. difficile infection data (up to April-June 2013). 12 September 2013. Disponible en: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139835857 (último acceso: 23 de octubre de 2013).
2. Meyer E et al. Associations between nosocomial meticillin-resistant Staphylococcus aureus and nosocomial Clostridium difficile-associated diarrhoea in 89 German hospitals. J Hosp Infect 2012;82(3):181-6.
3. Debast SB et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): update of the treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect. doi: 10.1111/1469-0691.12418.
4. Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol. 2011;8:17-26.
5. Oake N, et al. The effect of hospital-acquired Clostridium difficile infection on in-hospital mortality. Arch Intern Med 2010;170:1804-10.
6. Hensgens MP, et al. All-Cause and disease-specific mortality in hospitalized patients with Clostridium difficile infection: a Multicenter Cohort Study. Clin Infect Dis. 2013;56:1108-16.
7. Lowy I, et al. Treatment with Monoclonal Antibodies against Clostridium difficile Toxins. N Engl J Med. 2010;362;3:197-205.
8. Bouza E et al. Presented at 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona 2008. Abstract0464.
9. Louie TJ, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422-31.
10. Kelly CP, LaMont JT. Clostridium difficile - more difficult than ever. N Engl J Med. 2008;359(18):1932-1940.
11. Cornely OA et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12:281-289.
12. Cornely OA et al. Resolution of Clostridium difficile-Associated Diarrhea in Patients With Cancer Treated With Fidaxomicin or Vancomycin. J Clin Onc. 2013;31(19 ):2493-2499.
13. Mullane KM et al. Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections. Clin Infect Dis. 2011;53(5):440-447.
14. Mullane KM et al. Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials. Am J Nephrol. 2013;38(1):1-11.
15. Loo VG et al. A predominantly clonal multiinstitutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353 (23):2442-2449.
16. Campbell R et al. Length of stay and hospital costs among high-risk patients with hospital-origin Clostridium difficile-associated diarrhea. J. Med Econ. 2013;16(3 ):440-448.
17. Kim JH et al. Clostridium difficile infection in a long-term care facility: hospital-associated illness compared with long-term care-associated illness. Infect Control Hosp Epidemiol. 2011;32(7):656-660.
18. Zilberberg MD et al. Clostridium difficile-associated disease and mortality among the elderly critically ill. Crit Care Med. 2009;37(9):2583-2589.
19. Bauer MP et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect. 2009;15: 1067-1079.
20. Poutanen SM et al. Clostridium difficile-associated diarrhoea in adults. CMAJ. 2004;171:51-8.
21. Kelly CP et al. Clostridium difficile infection. Ann Rev Med. 1998;49:375-390.
22. Vonberg RP, et al. Costs of nosocomial Clostridium difficile-associated diarrhoea. J Hosp Infect. 2008;70:15-20.
23. Wilcox MH, et al. Financial burden of hospital-acquired Clostridium difficile infection. J Hosp Infect. 1996;34:23-30.
24. Dubberke MD, Wertheimer AI. Review of current literature on the economic burden of Clostridium difficile infection. Infect Contr Hosp Epidemiol. 2009; 30(1):57-66.
25. Magalini S, et al. An economic evaluation of Clostridium difficile infection management in an Italian hospital environment. Eur Rev Med Pharmacol Sci 2012;16:2136-41.
CONTACTO: Para más información, póngase en contacto con: Donna Wright,Ruder Finn, dwright@ruderfinn.co.uk,Tel.: +44-(0)20-7438-3085; Mindy Dooa,Astellas Pharma Europe Ltd., mindy.dooa@eu.astellas.comTel.: +44-(0)1784-419-444
